VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Becton, Dickinson and Company vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Becton, Dickinson and Company
BDX · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Becton, Dickinson and Company's moat claims, evidence, and risks.
View BDX analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: Becton, Dickinson and Company leads (66 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: Becton, Dickinson and Company has 5 segments (29.5% in Medical Essentials); Novartis AG has 5 segments (29.3% in Oncology).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Strong.
- Moat breadth: Becton, Dickinson and Company has 7 moat types across 3 domains; Novartis AG has 4 across 3.
Primary market context
Becton, Dickinson and Company
Medical Essentials
Single-use medical consumables and specimen collection systems
Global
Healthcare providers and clinical labs
Manufacturer
29.5%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Becton, Dickinson and Company strengths
Novartis AG strengths
Segment mix
Becton, Dickinson and Company segments
Full profile >Medical Essentials
Competitive
Connected Care
Oligopoly
BioPharma Systems
Oligopoly
Interventional
Competitive
Life Sciences
Oligopoly
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.